NCT00027703View on ClinicalTrials.gov

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

May 31, 2006

Conditions
Advanced Malignant MesotheliomaEpithelial MesotheliomaLocalized Malignant MesotheliomaRecurrent Malignant MesotheliomaSarcomatous Mesothelioma
Interventions
DRUG

gemcitabine hydrochloride

Given IV

DRUG

cisplatin

Given IV

BIOLOGICAL

bevacizumab

Given IV

OTHER

placebo

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00027703 - Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma | Biotech Hunter | Biotech Hunter